Effect of empagliflozin on all-cause hospitalization in EMPA-KIDNEY

被引：0
|
作者：
Uster, Anastasia [1 ]
Desai, Nihar [2 ]
Navaneethan, Sankar [3 ]
Pfarr, Egon [1 ]
Mazo, Anna Rita [1 ]
机构：
[1] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[2] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT USA
[3] Baylor Coll Med, Nephrol Sect, Dept Med, Selzman Inst Kidney Hlth, Houston, TX USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2024年 / 153卷
关键词：
D O I：
10.1016/j.metabol.2024.155857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0047
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus
    Feng, Kent Y.
    Gogate, Jagadish
    Damaraju, C. V.
    Li, JingWei
    Jardine, Meg J.
    Perkovic, Vlado
    Blais, Jaime D.
    Pfeifer, Michael
    Neal, Bruce
    Mahaffey, Kenneth W.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 116 : 17 - 18
  • [42] Impact of Relative Muscle Power on Hospitalization and All-Cause Mortality in Older Adults
    Losa-Reyna, Jose
    Alcazar, Julian
    Carnicero, Jose
    Alfaro-Acha, Ana
    Castillo-Gallego, Carmen
    Rosado-Artalejo, Cristina
    Rodriguez-Manas, Leocadio
    Ara, Ignacio
    Jose Garcia-Garcia, Francisco
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2022, 77 (04): : 781 - 789
  • [43] Insufficient Help for Activity of Daily Living Disabilities and Risk of All-Cause Hospitalization
    Xu, Huiping
    Covinsky, Kenneth E.
    Stallard, Eric
    Thomas, Joseph, III
    Sands, Laura P.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 (05) : 927 - 933
  • [44] ASSOCIATION BETWEEN ADHERENCE TO EVIDENCE-BASED HEART FAILURE DRUG TREATMENT AND ONE-YEAR ALL-CAUSE HOSPITALIZATION AND ALL-CAUSE MORTALITY
    Moisan, J.
    Girouard, C.
    Demers, E.
    Perez-Herrera, N.
    Zaour, N.
    Gregoire, J.
    VALUE IN HEALTH, 2015, 18 (07) : A377 - A377
  • [45] In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality
    Ebell, Mark H.
    AMERICAN FAMILY PHYSICIAN, 2016, 93 (05) : 410 - 410
  • [46] Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease
    Sato, Yuji
    Fujimoto, Shouichi
    Konta, Tsuneo
    Iseki, Kunitoshi
    Moriyama, Toshiki
    Yamagata, Kunihiro
    Tsuruya, Kazuhiko
    Narita, Ichiei
    Kondo, Masahide
    Kasahara, Masato
    Shibagaki, Yugo
    Asahi, Koichi
    Watanabe, Tsuyoshi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (02) : 388 - 394
  • [47] Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease
    Yuji Sato
    Shouichi Fujimoto
    Tsuneo Konta
    Kunitoshi Iseki
    Toshiki Moriyama
    Kunihiro Yamagata
    Kazuhiko Tsuruya
    Ichiei Narita
    Masahide Kondo
    Masato Kasahara
    Yugo Shibagaki
    Koichi Asahi
    Tsuyoshi Watanabe
    Clinical and Experimental Nephrology, 2018, 22 : 388 - 394
  • [48] ANEMIA AS A RISK FACTOR FOR ALL-CAUSE MORTALITY; OBSCURE SYNERGIC EFFECT OF CHRONIC KIDNEY DISEASE
    Sato, Yuji
    Fujimoto, Shouichi
    Konta, Tsuneo
    Iseki, Kunitoshi
    Moriyama, Toshiki
    Yamagata, Kunihiro
    Tsuruya, Kazuhiko
    Narita, Ichiei
    Kondo, Masahide
    Kasahara, Masato
    Shibagaki, Yugo
    Asahi, Koichi
    Watanabe, Tsuyoshi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [49] Effect of chronic kidney disease on all-cause mortality in tuberculosis disease: an Australian cohort study
    Beau Z. Carr
    Esther M. Briganti
    Joseph Musemburi
    Grant A. Jenkin
    Justin T. Denholm
    BMC Infectious Diseases, 22
  • [50] Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients
    Qu, Xiang
    Yao, Hui
    Chen, Changxi
    Kong, Shuting
    Sun, Lingyue
    Du, Leilei
    Liang, Siqi
    Gao, Zhan
    Zheng, Gaoshu
    Zheng, Minghua
    Zhao, Chuhuan
    Feng, Xiafei
    Wu, Gaojun
    Zhou, Hao
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345